Potential mechanism and prognostic value of promoter methylation of PRDM1 gene in diffuse large B cell lymphoma
10.3760/cma.j.issn.0529-5807.2016.12.004
- VernacularTitle:弥漫性大 B 细胞淋巴瘤中 PRDM 1基因甲基化状态与预后的相关性
- Author:
Xingyan ZHANG
1
;
Zhiping MA
;
Wenli CUI
;
Rong CHEN
;
Abulajiang GLINAER?
;
Na MIAO
;
Xinxia LI
Author Information
1. 新疆医科大学第一附属医院病理科
- Keywords:
Diffuse large B-cell lymphoma;
DNA Methylation;
Prognosis;
Cell lines
- From:
Chinese Journal of Pathology
2016;45(12):831-837
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate PRDM1 gene methylation status , immune classification and their prognostic significance in diffuse large B cell lymphoma (DLBCL).Methods Immunohistochemical (IHC) staining for CD20, CD10, bcl-2, bcl-6, PRDM1/Blimp-1 and MUM1 was carried out in 100 cases of DLBCL specimens and 20 reactive lymphoid proliferation samples . All patients were classified into germinal center B cell-like ( GCB) and activated B cell-like ( ABC) subtype according to Hans′algorithmin. PRDM1 gene methylation was detected by methylation-specific PCR ( MSP ) and its relationship with clinicopathologic parameters was analyzed .OCI-Ly1 ( GCB type) and OCI-Ly3 ( ABC type) cell lines were transfected by Small interfering RNA ( siRNA ) with cationic lipid reagent transfection mediated , and the PRDM1/Blimp-1 expression in before and after transfected cell lines were detected with reverse transcription -PCR and Western blot methods .The relationship between PRDM 1 gene methylation , clinicopathologic parameter and survival was analyzed using one-way analysis of variance .Results One hundred patients were classified into 73 (73%) cases of GCB subtypes and 27 (27%) cases of ABC.PRDM1/Blimp-1 was expressed in 21 DLBCL and highly expressed in 20 reactive lymphoid proliferation .PRDM1 gene methylation was detected in 23%(23/100) of DLBCL, while no methylation was detected in all 20 reactive lymphoid proliferation.The difference of the PRDM1 methylation status between DLBCL and the control samples was statistically significant (P=0.004).However, there was no significant correlation between the PRDM 1 gene methylation and clinicopathologic parameters ( P >0.05 ) .Reverse transcription-PCR and Western blot showed that PRDM1 gene expression was reduced in siRNA-induced group compared with blank control group and negative control group .One-way analysis of variance revealed that aged ≥60 years, performance status score above 3, and the presence of general symptoms were associated with significantly lower overall survival rate.Conclusions PRDM1 gene silencing with aberrant CpG methylation is probably one of the critical events in the oncogenesis of DLBCL .This may have important implications as a candidate marker for diagnosis and targeted gene therapy .Meanwhile in vitro siRNA transfected OCI-Ly1 and OCI-Ly3 cell lines confirm that PRDM1 gene is a suppressor gene in DLBCL and may represent a novel therapeutic target .
